{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:54:16Z","timestamp":1789505656574,"version":"build-2803163510"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To describe clinical course, characteristics, and outcome of reticular epithelial corneal edema (RECE) occurring as a not-so-infrequent adverse effect of a novel drug, Rho-kinase inhibitors (ROCK-I)- netarsudil (0.02%) and ripasudil (0.4%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This was a retrospective observational non-randomized study. In this study, 12 eyes of 11 patients presenting at a tertiary eye care center between April 2021 and September 2021 were included. All 12 eyes developed a distinctive honeycomb pattern of RECE after starting topical ROCK-I. All patients were subjected to detailed ophthalmic examinations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Eight patients were started on netarsudil (0.02%) and three on ripasudil (0.4%). Five eyes had a prior history of corneal edema. The remaining seven had the presence of ocular comorbidities predisposing to corneal edema. The average time for RECE occurrence was 25 days for netarsudil and 82 days for ripasudil. Visual acuity decreased in two eyes, remained unaffected in four eyes, and could not be quantified in four eyes due to preexisting profound visual impairment. Five eyes had symptoms of ocular surface discomfort associated with bullae. Symptoms and bullae resolved in all eyes in whom ROCK-I was stopped. The average time to resolution of RECE was 10 days for netarsudil and 25 days for ripasudil<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>RECE after ROCK-I occurs with the use of both netarsudil and ripasudil, although the characteristics differ. The presence of corneal edema and endothelial decompensation seem to be a risk factor, and cautious use is warranted in these patients. Four clinical stages of RECE are described. ROCK-I act as a double-edged sword in patients with endothelial decompensation. Large-scale studies are required to know the exact incidence, pathophysiology, and long-term consequences of the aforementioned side-effect.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijo.ijo_2865_21","type":"journal-article","created":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T07:53:23Z","timestamp":1648454003000},"page":"1163-1170","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":26,"title":["Reticular epithelial corneal edema as a novel side-effect of Rho Kinase Inhibitors: An Indian scenario"],"prefix":"10.4103","volume":"70","author":[{"given":"Mona","family":"Bhargava","sequence":"first","affiliation":[{"name":"Departments of Cornea and Ocular Surface, Aditya Birla Sankara Nethralaya, Kolkata, West Bengal (A Unit of Medical Research Foundation, Chennai), India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surajit","family":"Sen","sequence":"additional","affiliation":[{"name":"Department of Glaucoma, Aditya Birla Sankara Nethralaya, Kolkata, West Bengal (A Unit of Medical Research Foundation, Chennai), India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varsha","family":"Bhambhani","sequence":"additional","affiliation":[{"name":"Departments of Cornea and Ocular Surface, Aditya Birla Sankara Nethralaya, Kolkata, West Bengal (A Unit of Medical Research Foundation, Chennai), India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj Shekhar","family":"Paul","sequence":"additional","affiliation":[{"name":"Departments of Cornea and Ocular Surface, Aditya Birla Sankara Nethralaya, Kolkata, West Bengal (A Unit of Medical Research Foundation, Chennai), India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandana","family":"Dutta","sequence":"additional","affiliation":[{"name":"Department of Glaucoma, Aditya Birla Sankara Nethralaya, Kolkata, West Bengal (A Unit of Medical Research Foundation, Chennai), India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,3,22]]},"reference":[{"key":"B1-20240828","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/j.ophtha.2018.04.040","article-title":"Rho Kinase inhibitors as a novel treatment for glaucoma and ocular hypertension","volume":"125","author":"Tanna","year":"2018","journal-title":"Ophthalmology"},{"key":"B2-20240828","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1007\/s40265-014-0333-2","article-title":"Ripasudil: First global approval","volume":"74","author":"Garnock-Jones","year":"2014","journal-title":"Drugs"},{"key":"B3-20240828","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s40265-018-0877-7","article-title":"Netarsudil ophthalmic solution 0.02%: First global approval","volume":"78","author":"Hoy","year":"2018","journal-title":"Drugs"},{"key":"B4-20240828","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1089\/jop.2015.0116","article-title":"Effects of Rho Kinase inhibitors on intraocular pressure and aqueous humor dynamics in nonhuman primates and rabbits","volume":"32","author":"Toris","year":"2016","journal-title":"J Ocul Pharmacol Ther"},{"key":"B5-20240828","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/IJG.0b013e3182952213","article-title":"Effect of 0.04% AR-13324, a ROCK, and norepinephrine transporter inhibitor, on aqueous humor dynamics in normotensive monkey eyes","volume":"24","author":"Wang","year":"2015","journal-title":"J Glaucoma"},{"key":"B6-20240828","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.pneurobio.2015.06.002","article-title":"Towards axonal regeneration and neuroprotection in glaucoma: Rho kinase inhibitors as promising therapeutics","volume":"131","author":"Van de Velde","year":"2015","journal-title":"Prog Neurobiol"},{"key":"B7-20240828","doi-asserted-by":"crossref","first-page":"660","DOI":"10.2174\/1381612822666161205110027","article-title":"The role of rho kinase inhibitors in corneal endothelial dysfunction","volume":"23","author":"Okumura","year":"2017","journal-title":"Curr Pharm Des"},{"key":"B8-20240828","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ajpath.2014.10.023","article-title":"RhoA GTPase-induced ocular hypertension in a rodent model is associated with increased fibrogenic activity in the trabecular meshwork","volume":"185","author":"Pattabiraman","year":"2015","journal-title":"Am J Pathol"},{"key":"B9-20240828","article-title":"ROCK as a therapeutic target of diabetic retinopathy","author":"Arita","year":"2010","journal-title":"J Ophthalmol 2010"},{"key":"B10-20240828","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2147\/JEP.S259297","article-title":"Investigational Rho Kinase inhibitors for the treatment of glaucoma","volume":"13","author":"Al-Humimat","year":"2021","journal-title":"J Exp Pharmacol"},{"key":"B11-20240828","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1097\/IJG.0000000000001634","article-title":"Pooled efficacy and safety profile of netarsudil ophthalmic solution 0.02% in patients with open-angle glaucoma or ocular hypertension","volume":"29","author":"Singh","year":"2020","journal-title":"J Glaucoma"},{"key":"B12-20240828","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.ajo.2013.05.016","article-title":"Phase 2 randomized clinical study of a Rho kinase inhibitor, K-115, in primary open-angle glaucoma and ocular hypertension","volume":"156","author":"Tanihara","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"B13-20240828","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1186\/s12886-020-01490-1","article-title":"Safety and efficacy of ripasudil in Japanese patients with glaucoma or ocular hypertension: 12-month interim analysis of ROCK-J, a post-marketing surveillance study","volume":"20","author":"Tanihara","year":"2020","journal-title":"BMC Ophthalmol"},{"key":"B14-20240828","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1097\/IJG.0000000000001516","article-title":"Reticular corneal edema or corneal honeycombing in eyes treated with netarsudil: A case series","volume":"29","author":"Moumneh","year":"2020","journal-title":"J Glaucoma"},{"key":"B15-20240828","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ajo.2020.04.002","article-title":"Reticular bullous epithelial edema in corneas treated with netarsudil: A case series","volume":"217","author":"Wisely","year":"2020","journal-title":"Am J Ophthalmol"},{"key":"B16-20240828","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1097\/IJG.0000000000001636","article-title":"Reticular epithelial edema: An uncommon side effect of ROCK\/NET inhibitor netarsudil","volume":"29","author":"Chen","year":"2020","journal-title":"J Glaucoma"},{"key":"B17-20240828","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1097\/ICO.0000000000002621","article-title":"Transient reticular cystic corneal epithelial edema with topical netarsudil: A case series and review","volume":"40","author":"LoBue","year":"2021","journal-title":"Cornea"},{"key":"B18-20240828","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/ICO.0000000000002694","article-title":"Honeycomb Epithelial Edema Associated With Rho Kinase Inhibition: A Case Series and Review of the Literature","volume":"41","author":"Lyons","year":"2022","journal-title":"Cornea"},{"key":"B19-20240828","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/ICU.0000000000000579","article-title":"Descemet's stripping without endothelial keratoplasty","volume":"30","author":"Garcerant","year":"2019","journal-title":"Curr Opin Ophthalmol"},{"key":"B20-20240828","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/j.ophtha.2018.08.004","article-title":"Reticular epithelial edema in edematous corneas treated with netarsudil","volume":"125","author":"Fernandez","year":"2018","journal-title":"Ophthalmology"},{"key":"B21-20240828","first-page":"71","article-title":"Latest update in glaucoma: The first approvals for Rho Kinase inhibitors","volume":"30","author":"Bali","year":"2020","journal-title":"Delhi J Opthalmol"},{"key":"B22-20240828","doi-asserted-by":"crossref","first-page":"19640","DOI":"10.1038\/srep19640","article-title":"Effects of K-115 (Ripasudil), a novel ROCK inhibitor, on trabecular meshwork and Schlemm's canal endothelial cells","volume":"6","author":"Kaneko","year":"2016","journal-title":"Sci Rep"},{"key":"B23-20240828","doi-asserted-by":"crossref","first-page":"e0136802","DOI":"10.1371\/journal.pone.0136802","article-title":"Morphological changes of human corneal endothelial cells after rho-associated kinase inhibitor eye drop (ripasudil) administration: A prospective open-label clinical study","volume":"10","author":"Nakagawa","year":"2015","journal-title":"PLoS One"},{"key":"B24-20240828","doi-asserted-by":"crossref","first-page":"7560","DOI":"10.1167\/iovs.15-17887","article-title":"Rho-associated kinase inhibitor eye drop (ripasudil) transiently alters the morphology of corneal endothelial cells","volume":"56","author":"Okumura","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B25-20240828","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1097\/ICO.0000000000001209","article-title":"Descemetorhexis without grafting for Fuchs endothelial dystrophy\u2014Supplementation with topical ripasudil","volume":"36","author":"Moloney","year":"2017","journal-title":"Cornea"},{"key":"B26-20240828","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1089\/jop.2016.0028","article-title":"Ocular penetration and pharmacokinetics of ripasudil following topical administration to rabbits","volume":"32","author":"Isobe","year":"2016","journal-title":"J Ocul Pharmacol Ther"},{"key":"B27-20240828","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1089\/jop.2017.0023","article-title":"Discovery and preclinical development of netarsudil, a novel ocular hypotensive agent for the treatment of glaucoma","volume":"34","author":"Lin","year":"2018","journal-title":"J Ocul Pharmacol Ther"},{"key":"B28-20240828","article-title":"Application of Rho Kinase inhibitors for the treatment of corneal endothelial diseases","author":"Okumura","year":"2017","journal-title":"J Ophthalmol 2017"},{"key":"B29-20240828","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1586\/eop.12.12","article-title":"Comparisons of actin filament disruptors and Rho kinase inhibitors as potential antiglaucoma medications","volume":"7","author":"Tian","year":"2012","journal-title":"Expert Rev Ophthalmol"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijo.IJO_2865_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:10:31Z","timestamp":1787166631000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijo.IJO_2865_21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,22]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_2865_21","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,22]]},"assertion":[{"value":"2021-11-12","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-15","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}